Skip to main content
. 2022 Jan 19;37(14):3562–3569. doi: 10.1007/s11606-021-07331-1

Table 2.

Incidence of Primary Nonadherence in the Study Sample

Outcome measure Overall, n = 5146 GLP-1 agonist, n = 2435 SGLT2 inhibitor, n = 2711
30 days 1637 (31.8%) 726 (29.8%) 911 (33.6%)
14 days 2099 (40.8%) 950 (39%) 1149 (42.4%)
7 days 2343 (45.5%) 1067 (43.8%) 1276 (47.1%)